• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Vir Biotechnology upgraded by JP Morgan with a new price target

    3/6/23 7:36:08 AM ET
    $VIR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIR alert in real time by email
    JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
    Get the next $VIR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIR

    DatePrice TargetRatingAnalyst
    1/29/2024$23.00 → $9.00Overweight → Neutral
    JP Morgan
    9/8/2023$23.00 → $14.00Buy → Neutral
    BofA Securities
    3/6/2023$35.00 → $34.00Neutral → Overweight
    JP Morgan
    2/21/2023$41.00 → $53.00Neutral → Buy
    Goldman
    1/27/2023$18.00 → $30.00Underweight → Equal-Weight
    Morgan Stanley
    9/14/2022$40.00Outperform
    SVB Leerink
    9/9/2022$15.00Underweight
    Morgan Stanley
    3/3/2022$36.00 → $28.00Underperform → Neutral
    Baird
    More analyst ratings

    $VIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director More Robert J disposed of 14,027 shares and acquired 14,027 shares, decreasing direct ownership by 26% to 40,656 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      6/9/25 6:39:33 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bischofberger Norbert W disposed of 10,667 shares and acquired 10,667 units of Common Stock, decreasing direct ownership by 44% to 13,333 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      6/6/25 8:26:07 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 34% to 31,806 units (SEC Form 4)

      4 - Vir Biotechnology, Inc. (0001706431) (Issuer)

      6/2/25 7:31:04 PM ET
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care